Neuren Pharmaceuticals Ltd (NEU) — Capital Reinvestment Ratio

Latest as of June 2025: 0.00x

Neuren Pharmaceuticals Ltd (NEU) has a Capital Reinvestment Ratio of 0.00x as of June 2025, meaning it reinvests 0% of its operating cash flow (AU$128.31 Million) in capital expenditures (AU$5.00K). See NEU equity financing ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

AU$128.31 Million
AUD

Capital Expenditures

AU$5.00K
AUD

Data as of

Jun 2025
Most recent filing

Neuren Pharmaceuticals Ltd Capital Reinvestment Ratio (2018–2023)

This chart tracks Neuren Pharmaceuticals Ltd's Capital Reinvestment Ratio across 3 annual periods. Check NEU cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Neuren Pharmaceuticals Ltd (2018–2023)

Year-by-year Capital Reinvestment Ratio for Neuren Pharmaceuticals Ltd from 2018 to 2023. For live market cap and broader valuation context, see NEU market cap overview.

Year Reinvestment Ratio Operating CF (AUD) Capital Expenditures YoY Change
2023 0.00x AU$184.93 Million AU$40.00K ▼ -95.9%
2022 0.01x AU$3.60 Million AU$19.00K ▲ +181.9%
2018 0.00x AU$6.41 Million AU$12.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow